NDC 70529-045 Viadox

The NDC code 70529-045 is assigned by the FDA to the product Viadox which is product labeled by It3 Medical Llc. The product's dosage form is . The product is distributed in 3 packages with assigned NDC codes 70529-045-01 1 vial in 1 package / 1 ml in 1 vial, 70529-045-02 2 vial in 1 package / 1 ml in 1 vial, 70529-045-05 5 vial in 1 package / 1 ml in 1 vial. This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

A. Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:1. Endocrine disordersPrimary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtfulShock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspectedCongenital adrenal hyperplasiaNonsuppurative thyroiditisHypercalcemia associated with cancer2. Rheumatic disordersAs adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritisSynovitis of osteoarthritisRheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)Acute and subacute bursitisEpicondylitisAcute nonspecific tenosynovitisAcute gouty arthritisPsoriatic arthritisAnkylosing spondylitis3. Collagen diseasesDuring an exacerbation or as maintenance therapy in selected cases of:Systemic lupus erythematosusAcute rheumatic carditis4. Dermatologic diseasesPemphigusSevere erythema multiforme (Stevens-Johnson Syndrome)Exfoliative dermatitisBullous dermatitis herpetiformisSevere seborrheic dermatitisSevere psoriasisMycosis fungoides5. Allergic statesControl of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:Bronchial asthmaContact dermatitisAtopic dermatitisSerum sicknessSeasonal or perennial allergic rhinitisDrug hypersensitivity reactionsUrticarial transfusion reactionsAcute noninfectious laryngeal edema (epinephrine is the drug of first choice)6. Ophthalmic diseasesSevere acute and chronic allergic and inflammatory processes involving the eye, such as:Herpes zoster ophthalmicusIritis, iridocyclitisChorioretinitisDiffuse posterior uveitis and choroiditisOptic neuritisSympathetic ophthalmiaAnterior segment inflammationAllergic conjunctivitisAllergic corneal marginal ulcersKeratitis7. Gastrointestinal diseasesTo tide the patient over a critical period of the disease in:Ulcerative colitis (systemic therapy)Regional enteritis (systemic therapy)8. Respiratory diseasesSymptomatic SarcoidosisBerylliosisFulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapyLoeffler's syndrome not manageable by other meansAspiration pneumonitis9. Hematologic disordersAcquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated)Secondary thrombocytopenia in adultsErythroblastopenia (RBC anemia)Congenital (erythroid) hypoplastic anemia10. Neoplastic diseasesFor palliative management of:Leukemias and lymphomas in adultsAcute leukemia of childhood11. Edematous statesTo induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus12. Nervous systemAcute exacerbations of multiple sclerosis13. MiscellaneousTuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapyTrichinosis with neurologic or myocardial involvementDiagnostic testing of adrenocortical hyperfunctionCerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management.B. Intra-articular or soft tissue administration.When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:Synovitis of osteoarthritisRheumatoid arthritisAcute and subacute bursitisAcute gouty arthritisEpicondylitisAcute nonspecific tenosynovitisPost-traumatic osteoarthritisC. Intralesional administration.When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for:KeloidsLocalized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis)Discoid lupus erythematosusNecrobiosis lipoidica diabeticorumAlopecia areataThey also may be useful in cystic tumors of an aponeurosis tendon (ganglia).

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:

• RxCUI: 1812079 - dexAMETHasone sodium phosphate 10 MG in 1 ML Injection
• RxCUI: 1812079 - 1 ML dexamethasone phosphate 10 MG/ML Injection
• RxCUI: 1812079 - dexamethasone phosphate 10 MG (as dexamethasone sodium phosphate 11 MG) per 1 ML Injection